QGEN Qiagen NV
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Company profile
Ticker
QGEN
Exchange
CEO
Peer Michael Schatz
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
QGEN stock data
()
Calendar
6 Mar 19
16 Sep 19
31 Dec 19
News
Company financial data Financial data
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 1.5B | 1.42B | 1.34B | 1.28B | |
| Net income | 190.38M | 40.39M | 80.4M | 130.15M | |
| Diluted EPS | 0.82 | 0.17 | 0.34 | 0.55 | |
| Net profit margin | 12.68% | 2.85% | 6.01% | 10.16% | |
| Operating income | 266.58M | 153.42M | 98.83M | 179.5M | |
| Net change in cash | 68.49M | 1.98M | -80.03M | -43.19M | |
| Cash on hand | 208.08M | 139.6M | 137.62M | 217.64M | |
| Cost of revenue | 500.89M | 494.98M | 493.34M | 454.33M |
Financial data from Qiagen earnings reports
Financial report summary
?Competition
Guided Therapeutics • Nanogen • Cepheid • Biocept • Third Wave • China Medical • Rosetta Genomics • WaferGen Bio-systems • NanoString • Metastat
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AACR, Academy, alpelisib, anonymized, antimicrobial, anytime, ARESdb, ASH, Barcelona, BIOSCIENCE, Boehringer, Brexit, cardiovascular, carrier, chemotherapy, circumstance, clean, compensatory, consortia, constrained, contemporary, correct, customizable, cybersecurity, cystic, de, depict, disaggregate, disaggregation, disregarded, divergent, diversified, Diversifying, DNeasy, Earth, editing, Ellume, epidermal, expedient, FastSelect, feed, Fidelio, formula, Formulatrix, fraudulent, fungal, GBS, gonorrhoeae, Hamilton, healthy, hereof, Hodgkin, hormone, immature, immunotherapy, Ingelheim, Interbank, interface, invoice, invoiced, invoicing, IVDR, Leipzig, LIAISON, London, LungCancer, MDAX, MetaSUB, Migration, Minden, myeloma, Natera, NeuMoDx, Nevada, Nonemployee, novo, orderly, PACT, perpetual, Pfizer, posed, possession, Postbank, postmarket, PowerSoil, predetermined, ProstateCancerPanel, push, quicker, ramp, Reaping, reinforcing, reorganization, repetitive, SRL, straddle, stranded, synchronized, syndromic, tailored, TMB, tradable, UCP, ultrasensitive, UMI, unbilled, unclear, upfront, upward, vendor, VIE, whichever, won
Removed:
Abbott, adjunctive, AdnaGen, attractive, branch, BreastCancer, broaden, broker, called, cancelled, Carlsbad, cell, certifying, client, collectability, compact, consigned, consignment, consumption, curated, deliverable, demanding, digit, discontinuation, displacing, downstream, earliest, easy, EMD, emergency, equivocal, era, escrow, ESEQuant, expertly, expression, feedback, FIFO, Fisher, foregoing, Franklin, glucose, greatly, Grundstuecksverwaltungsgesellschaft, guaranteed, headcount, headwind, Hong, house, includable, Ingenuity, Inhibitor, IPO, Kong, Korean, LDT, lengthy, liquidated, livestock, loaned, Malaysia, Marseille, mbH, Merck, Millipore, Modaplex, neglect, older, optical, Pap, partly, perjury, persuasive, petition, plate, portable, preacquisition, Promega, pure, pursuing, QIAgility, QIAxcel, ratably, reagent, recover, relapse, remote, risky, Roche, roll, sharply, side, standardize, subdivision, succeed, surpassing, surtax, synergistic, Taiwan, tapping, tariff, Thermo, tube, twenty, unconsolidated, undisclosed, unprecedented, unsubordinated, urge, variant, visualizing, VSOE, warehouse, water
Financial reports
20-F
2018 FY
Annual report (foreign)
6 Mar 19
20-F
2017 FY
Annual report (foreign)
6 Mar 18
20-F
2016 FY
Annual report (foreign)
6 Mar 17
20-F
2015 FY
Annual report (foreign)
29 Feb 16
20-F
2014 FY
Annual report (foreign)
2 Mar 15
20-F
2013 FY
Annual report (foreign)
3 Mar 14
20-F
2012 FY
Annual report (foreign)
4 Mar 13
20-F
2011 FY
Annual report (foreign)
27 Mar 12
20-F
2010 FY
Annual report (foreign)
21 Mar 11
20-F
2009 FY
Annual report (foreign)
17 Mar 10
Current reports
6-K
Current report (foreign)
1 Aug 19
6-K
Current report (foreign)
1 Aug 19
6-K
Current report (foreign)
1 Aug 19
6-K
Current report (foreign)
25 Jul 19
6-K
Current report (foreign)
8 May 19
6-K
Current report (foreign)
8 May 19
6-K
Current report (foreign)
5 Feb 19
6-K
Current report (foreign)
7 Nov 18
6-K
Current report (foreign)
7 Nov 18
6-K
Current report (foreign)
31 Oct 18
Registration and prospectus
25
Voluntary exchange delisting
8 Jan 18
8-A12B
Registration of securities on exchange
20 Dec 17
S-8
Registration of securities for employees
5 May 17
S-8
Registration of securities for employees
2 Apr 15
S-8
Registration of securities for employees
17 Nov 11
424B5
Prospectus supplement for primary offering
25 Sep 09
424B5
Prospectus supplement for primary offering
23 Sep 09
F-3ASR
Automatic shelf registration (foreign)
22 Sep 09
424B3
Prospectus supplement
7 Aug 07
S-8
Registration of securities for employees
7 Aug 07
Proxies
No filings
Other
SD
Conflict minerals disclosure
8 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 19
SD
Conflict minerals disclosure
17 May 18
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 18
SD
Conflict minerals disclosure
24 Apr 17
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 17
UPLOAD
Letter from SEC
16 Aug 16
CORRESP
Correspondence with SEC
8 Aug 16
UPLOAD
Letter from SEC
28 Jul 16
SD
Conflict minerals disclosure
25 May 16